Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

Keros Therapeutics (KROS) Accumulated Depreciation & Amortization (2019 - 2025)

Keros Therapeutics filings provide 7 years of Accumulated Depreciation & Amortization readings, the most recent being $4.4 million for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 50.39% to $4.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.4 million, a 50.39% increase, with the full-year FY2025 number at $4.4 million, up 50.39% from a year prior.
  • Accumulated Depreciation & Amortization hit $4.4 million in Q4 2025 for Keros Therapeutics, up from $2.9 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $4.4 million in Q4 2025 to a low of $846000.0 in Q4 2021.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $1.7 million (2023), compared with a mean of $2.2 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: rose 17.34% in 2021 and later surged 71.45% in 2024.
  • Keros Therapeutics' Accumulated Depreciation & Amortization stood at $846000.0 in 2021, then surged by 37.47% to $1.2 million in 2022, then soared by 47.89% to $1.7 million in 2023, then surged by 71.45% to $2.9 million in 2024, then soared by 50.39% to $4.4 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $4.4 million (Q4 2025), $2.9 million (Q4 2024), and $1.7 million (Q4 2023) per Business Quant data.